Exhaustive study for aquisition of eary diagnostic or the anti-cancer drug sensitivity markers for lung cancer

在建立了肺结核单克隆抗体的基础上，我筛选了有用的早期血清学诊断标志物。结果，抗CAXII抗体被报道为asero诊断标志物（PLOS ONE 7（3）：e33952，2012）。另外，作者认为抗BSG和MHY 9抗体是肺癌病理诊断的有用标志物。通过对肿瘤相关自身抗体的分析，我发现抗Hu-C、Hu-D自身抗体是小细胞肺癌与大细胞神经内分泌癌鉴别诊断的新的血清学标志物（Int J Oncol 40：1957-1962，2012）Jt-半乳糖凝集素-3自身抗体被发现作为抗癌药物敏感性预测标志物。并且，我报道了使用相同患者的血清和肿瘤组织获得有用的血清诊断自身抗体的方法（Biomed Res 35（2）：133-143，2014）。

Erom established monoclonal antibodies for lung cancder, I selected useful early sero-diagnostic markers. As a results, anti-CAXII antibody was reported as asero-diagnostic marker (PLOS ONE 7(3): e33952, 2012). In addition, I submitted that antiBSG and MHY9 antibodies were useful markeres for pathological diagnosis of lung cancer. Ant-IMMT antibody was established as a sensitivity prediction marker of the platinum.By the analysis of tumor-associated autoantibodies, I reported antiHu-C, Hu-D autoantibodies were novel differential sero-diagnostic markers for small cell lung carcinoma from large cell neuroendocrine carcinoma (Int J Oncol 40: 1957-1962, 2012).Ant-Galectin-3 autoantibody was found as an anticancer drug sensitivity prediction marker. And, I reported methodology that aquisition of useful sero-diagnostic autoantibodies using the same patients' sera and tumor tissues (Biomed Res 35(2): 133-143, 2014.